Statin use and mortality of patients with prostate cancer: a meta-analysis
Authors Meng Y, Liao Y, Xu P, Wei W, Wang J
Received 10 October 2015
Accepted for publication 20 January 2016
Published 21 March 2016 Volume 2016:9 Pages 1689—1696
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ram Prasad
Peer reviewer comments 3
Editor who approved publication: Professor Daniele Santini
Yang Meng,1,* Yan-Biao Liao,2,* Peng Xu,1 Wu-Ran Wei,1 Jia Wang1
1Department of Urology, 2Department of Cardiology, West China Hospital of Sichuan University, Chengdu, People’s Republic of China
*These authors contributed equally to this work
Objective: The aim of this meta-analysis was to investigate the effect of statin use on the mortality of patients with prostate cancer (PCa).
Methods: An electronic search of PubMed, Embase, and CENTRAL databases from inception to August 2015 was performed to find eligible studies. Articles investigating the association between statin use and mortality of PCa were identified. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using random- or fixed-effects models.
Results: In total, 13 studies that enrolled 100,536 participants were included in this meta-analysis. Results showed that prediagnostic statin use had a significantly lower risk of both all-cause mortality (ACM; HR, 0.56; 95% CI, 0.38–0.83) and PCa-specific mortality (PCSM; HR, 0.53; 95% CI, 0.36–0.77). Similarly, postdiagnostic statin use was correlated with reductions in both ACM (HR, 0.77; 95% CI, 0.69–0.87) and PCSM (HR, 0.64; 95% CI, 0.52–0.79). When stratified by primary treatment, postdiagnostic use of statins had a 0.4-fold lower risk of ACM in patients with PCa who were treated with local therapy; both pre- and postdiagnostic use of statins was correlated with a significantly lower risk of PCSM in patients who were treated with androgen deprivation therapy.
Conclusion: Both pre- and postdiagnostic use of statins is associated with better overall survival and PCa-specific survival. This suggests a need for randomized controlled trials of statins in patients with PCa.
Keywords: prostate cancer, all-cause mortality, prostate cancer-specific mortality, statins
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]